Spyre Therapeutics Secures $403 Million in Upsized Public Offering

Apr 15, 2026 04:26 UTC

SYRE

Short term

Spyre Therapeutics has priced a public offering of 6.5 million shares to raise capital. The final proceeds significantly exceeded the company's initial target of $300 million.

Offering size increased to 6.5 million shares
Pricing established at $62.00 per share
Gross proceeds reached $403 million
Initial funding goal of $300 million surpassed
Strong investor demand drove the upsized deal

Spyre Therapeutics (SYRE) has announced the pricing of an upsized public offering of common stock, substantially increasing its available capital. The company issued 6.5 million shares at a price of $62.00 per share. The offering resulted in gross proceeds of approximately $403 million, before accounting for underwriting discounts and other associated costs. This final figure represents a notable increase over the company's original funding goal of $300 million. The decision to upsize the offering typically suggests strong institutional demand for the equity at the specified price point. For Spyre Therapeutics, this provides a larger-than-anticipated liquidity cushion to fund its operational requirements and strategic growth. While public offerings generally lead to share dilution, the successful oversubscription of this deal indicates a positive market reception to the company's current valuation and future prospects.